| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3193420 | Annals of Allergy, Asthma & Immunology | 2007 | 5 Pages |
Abstract
Use of prophylactic self-injectable epinephrine to prevent fatalities in children with mild venom anaphylaxis is not cost-effective if the annual venom-associated fatality rate is less than 2 per 100,000 persons at risk.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Marcus S. MD,